Cure8 research brief
Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.
This study suggests most pediatric and young-adult patients remained stable and continued therapy at 6 months, though drug levels were modestly lower.
Pediatric and young-adult patients with IBD, parents and caregivers, clinicians who manage pediatric IBD and patients on anti-TNF biologics, and researchers studying biosimilar switches.
The study reviewed 50 pediatric/young-adult patients who switched between May 2023 and July 2024. Clinical status by Physician Global Assessment was stable or improved in 86% (36/42) with available pre/post data, and 76% (38/50) remained on the biosimilar at 6 months.
Laboratory markers were reported as stable overall, but mean adalimumab trough levels decreased (reported from 18 to 15 µg/mL) with a p-value of 0.007. Twelve patients discontinued the biosimilar within 6 months; the authors report 7/12 discontinued due to the switch and 5/12 for reasons unrelated to switching.
Study limits and tone: This is a single-center, retrospective chart review with short (6-month) follow-up and a relatively small sample.
The extracted content is an abstract-level summary of the published journal article (structured content depth: abstract), not a full randomized trial; results should be interpreted cautiously and in discussion with clinical teams.
this is a retrospective single-center study with 6-month follow-up and the extraction is based on the article abstract. Changes in drug trough levels do not necessarily translate to clinical worsening for all patients; treatment decisions should be individualized and discussed with the treating clinician.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
